• Canada House Wellness Group (CSE:CHV) subsidiary, Abba Medix Corp, has registered its 100th medical patient in less than three months.
  • Abba has also added three more strains of medical cannabis to its current product portfolio, bringing their total of available strains to four. 
  • Abba expects to see patient growth rates rise as customer awareness and satisfaction increase.
  • Canada House’s share price is up 20 per cent, with shares trading at $0.03 apiece.

Canada House Wellness Group (CHV) subsidiary, Abba Medix, recently registered its 100th medical patient in less than three months.

This milestone is yet another indicator of the success that the medical cannabis industry is currently experiencing in Canada.

Abba has also recently added three more strains of medical cannabis to its current product portfolio. As a result, Abba now has a total of four strains available for sale to their registered patients. 

Abba’s customer base is gradually becoming more aware of and satisfied with the variety of medical-grade cannabis on offer. Canada House expects to see a considerable rise in patient growth rates in the future.

According to Canada House CEO Chris Churchill-Smith, Abba plans to “expand relationships with users of medical cannabis and cannabis clinics across the country. In addition, we plan to listen to our patients and increase the selection of cannabis products to meet their needs”.

Michael Orrbrooke, President of Abba and Chief Revenue Officer of Canada House, spoke about the company’s plans for future growth. “As Abba’s patient base continues to grow, we will strategically and selectively add complementary strains that our patients covet.”

“In addition to offering a more comprehensive selection of strains, we intend to offer our products in new formats, to provide our medical patients with many options.”

Canada House’s share price is up 20 per cent, with shares trading at $0.03 apiece.

More From The Market Online

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.

The Market Online’s Weekly Cannabis Report – April 12, 2024

Canada’s cannabis stock market fluctuated this week thanks to a combination of industry-specific developments and broader market trends

Avicanna completes topical gel study

Avicanna (TSX:AVCN) has completed its observational real-world evidence study of its RHO Phyto branded cannabigerol gel.